首頁 › 三陰性乳癌 › 賓夕法尼亞州 › Pittsburgh
Pittsburgh, PA 的 三陰性乳癌 臨床試驗
11 項針對 三陰性乳癌 的研究正在 Pittsburgh（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Pittsburgh Medical Center, Pittsburgh
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
招募中
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
招募中1 期
- UPMC, Pittsburgh
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- UPMC Magee-Womens Hospital, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Pittsburgh
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0360, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Allegheny Health Network, Pittsburgh
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
招募中觀察性研究
- UPMC Hillman Cancer, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- University of Pittsburgh Medical Center, Pittsburgh
其他城市的 三陰性乳癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Los Angeles, CA27 項研究
- Boston, MA26 項研究
- San Antonio, TX23 項研究
- St. Louis, MO21 項研究
- Arlington, VA20 項研究
- Atlanta, GA20 項研究
- Dallas, TX18 項研究
- Chicago, IL16 項研究
- Columbus, OH16 項研究
Pittsburgh 的其他研究
- 非小細胞肺癌48 項研究
- 癌症（所有類型）41 項研究
- 乳癌39 項研究
- 大腸直腸癌32 項研究
- 轉移性癌症31 項研究
- 黑色素瘤31 項研究
- 卵巢癌30 項研究
- 子宮內膜癌23 項研究
- 前列腺癌23 項研究
- 肺癌23 項研究
- 頭頸部鱗狀細胞癌22 項研究
- 中風22 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。